ABX advanced biochemical compounds GmbH
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 1997-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.abx.de
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- ABX advanced biochemical compounds GmbH
- Target Recruit Count
- 380
- Registration Number
- NCT06122584
- Locations
- 🇫🇷
CHRU de Nancy, Nancy, France
🇪🇸Hospital Del Mar, Barcelona, Spain
🇪🇸Hospital Vithas Valencia 9 de Octubre, Valencia, Spain
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
- Conditions
- Prostate CancerProstate Cancer Recurrent
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- ABX advanced biochemical compounds GmbH
- Target Recruit Count
- 136
- Registration Number
- NCT04742361
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
- Conditions
- Prostate Cancer RecurrentProstate Cancer
- Interventions
- Drug: F-18-PSMA-1007Drug: F-18-Fluorocholine
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- ABX advanced biochemical compounds GmbH
- Target Recruit Count
- 200
- Registration Number
- NCT04102553
- Locations
- 🇫🇷
Centre Jean Perrin Clermont-Ferrand, Clermont-Ferrand, France
🇫🇷Centre Léon Bérard LUMEN, Lyon, France
🇫🇷Hôpitaux de Brabois (Vandoeuvre-les-Nancy), Nancy, France
News
Primo Biotechnology Raises NT$220M Series A to Advance Radioligand Theranostics Platform
Primo Biotechnology completed a NT$220 million Series A funding round, bringing total capital raised to over NT$500 million to accelerate radioligand theranostics development.
Primo and ABX Partner to Introduce Advanced PSMA-Targeting Radiotracer for Prostate Cancer Diagnosis in Taiwan
Primo Biotechnology has formed a strategic partnership with Germany's ABX to introduce PB01, an advanced diagnostic radiotracer for prostate cancer, to the Taiwanese market amid rising disease incidence and mortality rates.